Physician profile

Ian B Hoffman

Pulmonary Disease · Baltimore, MD

NPI 1558494773

$2,615.26

in general payments reported to CMS, 2019-2025

22 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $836.74 2019-2021
Boehringer Ingelheim Pharmaceuticals, INC. $670.61 2019-2021
Astrazeneca Pharmaceuticals LP $356.33 2019-2021
Insmed, INC. $169.18 2019-2020
Novartis Pharmaceuticals Corporation $128.79 2019
Regeneron Healthcare Solutions, INC. $59.86 2021
Mallinckrodt Enterprises LLC $50.86 2019
Grifols USA, LLC $50.05 2019-2020
Genentech USA, INC. $45.94 2019
Biomerieux INC $26.74 2019
Abbvie INC. $25.12 2021
Gilead Sciences, INC. $22.02 2021
Actelion Pharmaceuticals US, INC. $21.53 2021
Genzyme Corporation $20.77 2021
Allergan, INC. $20.02 2020
Show all 22 companies
CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $18.88 2020
Sobi, INC $17.81 2019
Sanofi Pasteur INC. $17.67 2020
Sunovion Pharmaceuticals INC. $16.68 2019
Mylan Specialty L.P. $14.61 2019
Inogen, INC. $13.00 2019
Ucb, INC. $12.05 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ian B Hoffman

$2,615.26

in general payments reported 2019-2025

Years
2019-2021
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/24825/ian-b-hoffman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.